Perspectives on the role of mTORC2 in B lymphocyte development, immunity and tumorigenesis

Abstract

Mammalian target of rapamycin complex 2 (mTORC2) is a key downstream mediator of phosphoinositol-3-kinase (PI3K) dependent growth factor signaling. In lymphocytes, mTORC2 has emerged as an important regulator of cell development, homeostasis and immune responses. However, our current understanding of mTORC2 functions and the molecular mechanisms regulating mTORC2 signaling in B and T cells are still largely incomplete. Recent studies have begun to shed light on this important pathway. We have previously reported that mTORC2 mediates growth factor dependent phosphorylation of Akt and facilitates Akt dependent phosphorylation and inactivation of transcription factors FoxO1 and FoxO3a. We have recently explored the functions of mTORC2 in B cells and show that mTORC2 plays a key role in regulating survival and immunoglobulin (Ig) gene recombination of bone marrow B cells through an Akt2-FoxO1 dependent mechanism. Ig recombination is suppressed in proliferating B cells to ensure that DNA double strand breaks are not generated in actively dividing cells. Our results raise the possibility that genetic or pharmacologic inhibition of mTORC2 may promote B cell tumor development as a result of inefficient suppression of Ig recombination in dividing B cells. We also propose a novel strategy to treat cancers based on our recent discovery that mTORC2 regulates Akt protein stability.

Keywords

mTOR / lymphocyte / B cell / cancer / mTORC2 / FoxO / Akt / Sin1

References

[1] Amin, R.H., and Schlissel, M.S. (2008). Foxo1 directly regulates the transcription of recombination-activating genes during B cell development. Nat Immunol 9, 613–622 .18469817
[2] Baracho, G.V., Miletic, A.V., Omori, S.A., Cato, M.H., and Rickert, R.C. (2011). Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation. Curr Opin Immunol 23, 178–183 .21277760
[3] Calamito, M., Juntilla, M.M., Thomas, M., Northrup, D.L., Rathmell, J., Birnbaum, M.J., Koretzky, G., and Allman, D. (2010). Akt1 and Akt2 promote peripheral B-cell maturation and survival. Blood 115, 4043–4050 .20042722
[4] Chen, J., Limon, J.J., Blanc, C., Peng, S.L., and Fruman, D.A. (2010). Foxo1 regulates marginal zone B-cell development. Eur J Immunol 40, 1890–1896 .20449867
[5] Chowdhury, D., and Sen, R. (2004). Regulation of immunoglobulin heavy-chain gene rearrangements. Immunol Rev 200, 182–196 .15242405
[6] Dengler, H.S., Baracho, G.V., Omori, S.A., Bruckner, S., Arden, K.C., Castrillon, D.H., DePinho, R.A., and Rickert, R.C. (2008). Distinct functions for the transcription factor Foxo1 at various stages of B cell differentiation. Nat Immunol 9, 1388–1398 .18978794
[7] Facchinetti, V., Ouyang, W., Wei, H., Soto, N., Lazorchak, A., Gould, C., Lowry, C., Newton, A.C., Mao, Y., Miao, R.Q., (2008b). The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J 27, 1932–1943 .18566586
[8] Feldman, M.E., Apsel, B., Uotila, A., Loewith, R., Knight, Z.A., Ruggero, D., and Shokat, K.M. (2009). Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 7, e38.19209957
[9] Frias, M.A., Thoreen, C.C., Jaffe, J.D., Schroder, W., Sculley, T., Carr, S.A., and Sabatini, D.M. (2006). mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol 16, 1865–1870 .16919458
[10] Gingras, A.C., Raught, B., and Sonenberg, N. (2004). mTOR signaling to translation. Curr Top Microbiol Immunol 279, 169–197 .14560958
[11] Goldmit, M., and Bergman, Y. (2004). Monoallelic gene expression: a repertoire of recurrent themes. Immunol Rev 200, 197–214 .15242406
[12] Grawunder, U., Leu, T.M., Schatz, D.G., Werner, A., Rolink, A.G., Melchers, F., and Winkler, T.H. (1995). Down-regulation of RAG1 and RAG2 gene expression in preB cells after functional immunoglobulin heavy chain rearrangement. Immunity 3, 601–608 .7584150
[13] Guertin, D.A., and Sabatini, D.M. (2009). The pharmacology of mTOR inhibition. Sci Signal 2, pe24.19383975
[14] Guertin, D.A., Stevens, D.M., Thoreen, C.C., Burds, A.A., Kalaany, N.Y., Moffat, J., Brown, M., Fitzgerald, K.J., and Sabatini, D.M. (2006). Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell 11, 859–871 .17141160
[15] Harris, T.E., and Lawrence, J.C. Jr. (2003). TOR signaling. Sci STKE 2003, re15.14668532
[16] Hasham, M.G., Donghia, N.M., Coffey, E., Maynard, J., Snow, K.J., Ames, J., Wilpan, R.Y., He, Y., King, B.L., and Mills, K.D. (2010). Widespread genomic breaks generated by activation-induced cytidine deaminase are prevented by homologous recombination. Nat Immunol 11, 820–826 .20657597
[17] Herzog, S., Hug, E., Meixlsperger, S., Paik, J.H., DePinho, R.A., Reth, M., and Jumaa, H. (2008). SLP-65 regulates immunoglobulin light chain gene recombination through the PI(3)K-PKB-Foxo pathway. Nat Immunol 9, 623–631 .18488031
[18] Herzog, S., Reth, M., and Jumaa, H. (2009). Regulation of B-cell proliferation and differentiation by pre-B-cell receptor signalling. Nat Rev Immunol 9, 195–205 .19240758
[19] Hietakangas, V., and Cohen, S.M. (2007). Re-evaluating AKT regulation: role of TOR complex 2 in tissue growth. Genes Dev 21, 632–637 .17369395
[20] Hoang, B., Frost, P., Shi, Y., Belanger, E., Benavides, A., Pezeshkpour, G., Cappia, S., Guglielmelli, T., Gera, J., and Lichtenstein, A. (2010). Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor. Blood 116, 4560–4568 .20686120
[21] Ikenoue, T., Inoki, K., Yang, Q., Zhou, X., and Guan, K.L. (2008). Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. EMBO J 27, 1919–1931 .18566587
[22] Jacinto, E., Facchinetti, V., Liu, D., Soto, N., Wei, S., Jung, S.Y., Huang, Q., Qin, J., and Su, B. (2006). SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127, 125–137 .16962653
[23] Janes, M.R., Limon, J.J., So, L., Chen, J., Lim, R.J., Chavez, M.A., Vu, C., Lilly, M.B., Mallya, S., Ong, S.T., (2010). Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med 16, 205–213 .20072130
[24] Jung, D., and Alt, F.W. (2004). Unraveling V(D)J recombination; insights into gene regulation. Cell 116, 299–311 .14744439
[25] Kharas, M.G., Deane, J.A., Wong, S., O’Bosky, K.R., Rosenberg, N., Witte, O.N., and Fruman, D.A. (2004). Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells. Blood 103, 4268–4275 .14976048
[26] Kraus, M., Alimzhanov, M.B., Rajewsky, N., and Rajewsky, K. (2004). Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell 117, 787–800 .15186779
[27] Lazorchak, A.S., Liu, D., Facchinetti, V., Di Lorenzo, A., Sessa, W.C., Schatz, D.G., and Su, B. (2010). Sin1-mTORC2 suppresses rag and il7r gene expression through Akt2 in B cells. Mol Cell 39, 433–443 .20705244
[28] Li, Z., Dordai, D.I., Lee, J., and Desiderio, S. (1996). A conserved degradation signal regulates RAG-2 accumulation during cell division and links V(D)J recombination to the cell cycle. Immunity 5, 575–589 .8986717
[29] Llorian, M., Stamataki, Z., Hill, S., Turner, M., and M?rtensson, I.L. (2007). The PI3K p110delta is required for down-regulation of RAG expression in immature B cells. J Immunol 178, 1981–1985 .17277100
[30] Mackay, F., Figgett, W.A., Saulep, D., Lepage, M., and Hibbs, M.L. (2010). B-cell stage and context-dependent requirements for survival signals from BAFF and the B-cell receptor. Immunol Rev 237, 205–225 .20727038
[31] Malin, S., McManus, S., and Busslinger, M. (2010). STAT5 in B cell development and leukemia. Curr Opin Immunol 22, 168–176 .20227268
[32] Manning, G., Whyte, D.B., Martinez, R., Hunter, T., and Sudarsanam, S. (2002). The protein kinase complement of the human genome. Science 298, 1912–1934 .12471243
[33] Oh, W.J., Wu, C.C., Kim, S.J., Facchinetti, V., Julien, L.A., Finlan, M., Roux, P.P., Su, B., and Jacinto, E. (2010). mTORC2 can associate with ribosomes to promote cotranslational phosphorylation and stability of nascent Akt polypeptide. EMBO J 29, 3939–3951 .21045808
[34] Okkenhaug, K., Bilancio, A., Farjot, G., Priddle, H., Sancho, S., Peskett, E., Pearce, W., Meek, S.E., Salpekar, A., Waterfield, M.D., (2002). Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 297, 1031–1034 .12130661
[35] Patke, A., Mecklenbr?uker, I., Erdjument-Bromage, H., Tempst, P., and Tarakhovsky, A. (2006). BAFF controls B cell metabolic fitness through a PKC beta- and Akt-dependent mechanism. J Exp Med 203, 2551–2562 .17060474
[36] Ramadani, F., Bolland, D.J., Garcon, F., Emery, J.L., Vanhaesebroeck, B., Corcoran, A.E., and Okkenhaug, K. (2010). The PI3K isoforms p110alpha and p110delta are essential for pre-B cell receptor signaling and B cell development. [Electronic Resource] Sci Signal 3, ra60.20699475
[37] Sarbassov, D.D., Ali, S.M., Sengupta, S., Sheen, J.H., Hsu, P.P., Bagley, A.F., Markhard, A.L., and Sabatini, D.M. (2006). Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22, 159–168 .16603397
[38] Sarbassov, D.D., Guertin, D.A., Ali, S.M., and Sabatini, D.M. (2005). Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098–1101 .15718470
[39] Schlissel, M.S. (2003). Regulating antigen-receptor gene assembly. Nat Rev Immunol 3, 890–899 .14668805
[40] Schlissel, M.S., and Stanhope-Baker, P. (1997). Accessibility and the developmental regulation of V(D)J recombination. Semin Immunol 9, 161–170 .9200327
[41] Srinivasan, L., Sasaki, Y., Calado, D.P., Zhang, B., Paik, J.H., DePinho, R.A., Kutok, J.L., Kearney, J.F., Otipoby, K.L., and Rajewsky, K. (2009). PI3 kinase signals BCR-dependent mature B cell survival. Cell 139, 573–586 .19879843
[42] Stadanlick, J.E., Kaileh, M., Karnell, F.G., Scholz, J.L., Miller, J.P., Quinn, W.J. 3rd, Brezski, R.J., Treml, L.S., Jordan, K.A., Monroe, J.G., (2008). Tonic B cell antigen receptor signals supply an NF-kappaB substrate for prosurvival BLyS signaling. Nat Immunol 9, 1379–1387 .18978795
[43] Staszewski, O., Baker, R.E., Ucher, A.J., Martier, R., Stavnezer, J., and Guikema, J.E. (2011). Activation-induced cytidine deaminase induces reproducible DNA breaks at many non-Ig Loci in activated B cells. Mol Cell 41, 232–242 .21255732
[44] Tsai, A.G., Lu, H., Raghavan, S.C., Muschen, M., Hsieh, C.L., and Lieber, M.R. (2008). Human chromosomal translocations at CpG sites and a theoretical basis for their lineage and stage specificity. Cell 135, 1130–1142 .19070581
[45] Verkoczy, L., Duong, B., Skog, P., A?t-Azzouzene, D., Puri, K., Vela, J.L., and Nemazee, D. (2007). Basal B cell receptor-directed phosphatidylinositol 3-kinase signaling turns off RAGs and promotes B cell-positive selection. J Immunol 178, 6332–6341 .17475862
[46] Wang, J.H., Alt, F.W., Gostissa, M., Datta, A., Murphy, M., Alimzhanov, M.B., Coakley, K.M., Rajewsky, K., Manis, J.P., and Yan, C.T. (2008). Oncogenic transformation in the absence of Xrcc4 targets peripheral B cells that have undergone editing and switching. J Exp Med 205, 3079–3090 .19064702
[47] Wang, J.H., Gostissa, M., Yan, C.T., Goff, P., Hickernell, T., Hansen, E., Difilippantonio, S., Wesemann, D.R., Zarrin, A.A., Rajewsky, K., (2009). Mechanisms promoting translocations in editing and switching peripheral B cells. Nature 460, 231–236 .19587764
[48] Wicker, L.S., Boltz, R.C. Jr, Matt, V., Nichols, E.A., Peterson, L.B., and Sigal, N.H. (1990). Suppression of B cell activation by cyclosporin A, FK506 and rapamycin. Eur J Immunol 20, 2277–2283 .1700753
[49] Wu, Y.-T., Ouyang, W., Lazorchak, A.S., Liu, D., Shen, H.-M., and Su, B. (2011). mTOR Complex 2 Targets Akt for Proteasomal Degradation via Phosphorylation at the Hydrophobic Motif. J Biol Chem 286, 14190–14198 .
[50] Wullschleger, S., Loewith, R., and Hall, M.N. (2006a). TOR signaling in growth and metabolism. Cell 124, 471–484 .16469695
[51] Yamane, A., Resch, W., Kuo, N., Kuchen, S., Li, Z., Sun, H.W., Robbiani, D.F., McBride, K., Nussenzweig, M.C., and Casellas, R. (2011). Deep-sequencing identification of the genomic targets of the cytidine deaminase AID and its cofactor RPA in B lymphocytes. Nat Immunol 12, 62–69 .21113164
[52] Zeng, Z., Sarbassov, D.D., Samudio, I.J., Yee, K.W.L., Munsell, M.F., Ellen Jackson, C., Giles, F.J., Sabatini, D.M., Andreeff, M., and Konopleva, M. (2007). Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML Blood 109, 3509– 3512 .
[53] Zhang, L., Reynolds, T.L., Shan, X., and Desiderio, S. (2011). Coupling of V(D)J recombination to the cell cycle suppresses genomic instability and lymphoid tumorigenesis. Immunity 34, 163–174 .21349429
[54] Zhu, C., Mills, K.D., Ferguson, D.O., Lee, C., Manis, J., Fleming, J., Gao, Y., Morton, C.C., and Alt, F.W. (2002). Unrepaired DNA breaks in p53-deficient cells lead to oncogenic gene amplification subsequent to translocations. Cell 109, 811–821 .12110179